TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2595326
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream 5%
Study: 28492789
Drug: Long-acting lignocaine-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting lignocaine-based blood cardioplegia (single dose)
Study: 21913385
Drug: Ultrasound cavitation
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound cavitation therapy (USC) using Sonoca‐180 unit
Study: 18642029
Drug: Octreotide 30
Normalized name: octreotide 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide 30 mg im on day 1
Study: 18642029
Drug: Octreotide 30
Normalized name: octreotide 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide 30 mg on day 1 plus Imatinib 400 mg po daily
Study: 18642029
Drug: Oxaliplatin on
Normalized name: Oxaliplatin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin on day 1 (60 mg-90 mg/m2)
Study: 18642029
Drug: Oxaliplatin on
Normalized name: Oxaliplatin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin on day 1, 8, 15 (20 mg-30 mg/m2) plus octreotide 30 mg on day 1 plus imatinib 400 mg po daily
Study: 15633480
Drug: Sentinel lymph
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sentinel lymph node biopsy (SLNB) using subdermal or peritumoral injection of vital blue dye and/or both substances together.
Study: 11425807
Drug: Rofecoxib (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib (25 mg, orally, once daily for 9 consecutive days)
Study: 8574511
Drug: midazolam 100
Normalized name: midazolam 100 MG in 100 mL Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: midazolam 100 micrograms/kg by jet‐injection (JI)
Study: 8574511
Drug: midazolam 150
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: midazolam 150 micrograms/kg by jet‐injection (JI)
Study: 8574511
Drug: midazolam 200
Normalized name: midazolam 200 mg/200 mL-D5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: midazolam 200 micrograms/kg by jet‐injection (JI)
Study: 2203257
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (800 mg dl-alpha-tocopheryl acetate)
Study: 393520
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release propranolol capsules 160 mg once daily
Study: 393520
Drug: Standard propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard propranolol tablets 40 mg four times daily
Study: 28500900
Drug: Autologous mesenchymal
Normalized name: AUTOLOGOUS MESENCHYMAL STROMAL CELLS SECRETING NEUROTROPHIC FACTORS
DrugBank: Debamestrocel (DB17934)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous mesenchymal stem cells (MSC) therapy with a target dose of 1×10^6 cells/kg intravenously and 0.1×10^6 cells/kg intrathecally
Study: 28500900
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with anti-epileptic drugs (AED)
Study: 23562198
Drug: TAA HFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAA HFA at 14, 110, or 440 micrograms once daily
Study: 23562198
Drug: TAA CFC
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAA CFC at 14, 110, or 440 micrograms once daily
Study: 23562198
Drug: TAA HFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAA HFA and TAA CFC formulations
Study: 23562198
Drug: TAA HFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAA HFA at 7 micrograms per nostril once daily
Study: 17174015
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose selenium (Se+ group, 474, 316, 158 microg/day for 3 days followed by 31.6 microg/day)
Study: 17174015
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose selenium (Se+ group)
Study: 17174015
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Se- group, standard dose of 31.6 microg/day)
Study: 15143088
Drug: Dalteparin (5,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin (5,000 IU, once-daily subcutaneous injection)
Study: 29499060
Drug: Point of
Normalized name: Precision Point of Care Test Strip
Approvals — FDA: no, EMA: no, PMDA: no
Description: Point of Care CD4 + Household Isoniazid Preventive Therapy (HH-IPT)
Study: 26927166
Drug: CHO +
Normalized name: G-CSF (CHO cell derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO + WP (20 g whey protein isolate)
Study: 19903626
Drug: SockIt! Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: SockIt! Oral Pain Gel applied to dentures
Study: 19903626
Drug: No topical
Normalized name: Altreno Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No topical treatment
Study: 2311145
Drug: Epidural epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural epinephrine (5 micrograms.ml‐1) added to bupivacaine (0.75 per cent)
Study: 6770801
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of sustained-release capsules once a day
Study: 6770801
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of capsules twice a day
Study: 6770801
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg of tablets four times a day
Study: 28816142
Drug: Vorinostat 400
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vorinostat 400 mg orally once daily for 14 days with concurrent stereotactic radiosurgery (SRS)
Study: 28816142
Drug: Vorinostat 200
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vorinostat 200 mg and 300 mg doses
Study: 15028938
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL acetic acid gel, intravaginally twice daily for 7 days
Study: 15028938
Drug: Placebo gel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel, intravaginally twice daily for 7 days
Study: 11573636
Drug: Tramadol 2
Normalized name: traMADol 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 2 mg kg(-1) i.v.
Study: 11573636
Drug: Tramadol 2
Normalized name: traMADol 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 2 mg kg(-1) i.v. and Placebo
Study: 7887134
Drug: NADH, 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: NADH, 25 mg, given intravenously once a day for four days, followed by 25 mg NADH intramuscularly after 2 and 4 weeks
Study: 3039130
Drug: Unprocessed bran
Normalized name: bran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unprocessed bran 5 g three times daily
Study: 3039130
Drug: Unprocessed bran
Normalized name: bran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unprocessed bran 2.5 g three times daily
Study: 16532872
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (traditional treatment)
Study: 28578607
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate plus prednisone (1000 mg daily, given once daily as four 250-mg tablets; prednisone 5 mg daily)
Study: 11932859
Drug: Flexible frozen
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible frozen gel pack
Study: 9800740
Drug: Tamoxifen (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (40 mg per day)
Study: 2548551
Drug: Cilazapril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril (4 mg)
Study: 132566
Drug: Ipratropiumbromide (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipratropiumbromide (30 mg or more)
Study: 29699723
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg ketamine racemate
Study: 20156055
Drug: Arm I:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm I: Isoniazid, rifampicin, and pyrazinamide simultaneously at full dosage from day 1
Study: 20156055
Drug: Arm II:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm II: Drugs administered according to American Thoracic Society guidelines
Study: 20156055
Drug: Arm III:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm III: Drugs administered according to British Thoracic Society guidelines
Study: 18030209
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) replacement therapy (0.25 mg/kg subcutaneously each week)
Study: 7884421
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy regimen (cyclophosphamide 7.2 g/m2, carmustine 300 mg/m2 or 600 mg/m2, etoposide 2,400 mg/m2) followed by allogeneic bone marrow transplantation (allo BMT)
Study: 7884421
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy regimen (carmustine 600 mg/m2)
Study: 7884421
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy regimen (carmustine 300 mg/m2)
Study: 7884421
Drug: Allo BMT
Normalized name: allo-2-hydroxycitric acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allo BMT following high-dose CBV regimen
Study: 638577
Drug: Aminophylline 1
Normalized name: aminophylline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline 1 mg/min
Study: 31744484
Drug: Peer evaluation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer evaluation in pharmacodynamics items (PE-PD)
Study: 31744484
Drug: Peer evaluation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer evaluation in pharmacokinetics items (PE-PK)
Study: 31744484
Drug: Teachers' marks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teachers' marks for oral presentation (PE-PD)
Study: 31744484
Drug: Teachers' marks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teachers' marks for oral presentation (PE-PK)
Study: 20146877
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg twice a day (bid)
Study: 20146877
Drug: Tramadol HCl
Normalized name: tramadol HCl
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol HCl 50 mg four times a day (qid)
Study: 16321614
Drug: Bradykinin B(2)
Normalized name: Bradykinin
DrugBank: Bradykinin (DB12126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bradykinin B(2) receptor antagonist HOE 140 (100 mug/kg)
Study: 12029261
Drug: Antithrombin III
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombin III (ATIII) administration
Study: 12029261
Drug: Heparin (concomitant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (concomitant use)
Study: 30421441
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) bolus of cangrelor (30 μg/kg) followed by a 120‐minute infusion (4 μg/kg/min)
Study: 23125443
Drug: Ad26.ENVA.01 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad26.ENVA.01 vaccine
Study: 10482146
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus ticlopidine
Study: 11358941
Drug: Adrenomedullin high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenomedullin high dose (5.8 pmol/kg per minute)
Study: 11358941
Drug: Adrenomedullin low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenomedullin low dose (2.9 pmol/kg per minute)
Study: 9433365
Drug: Continuous administration
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous administration of 10 mg cetirizine daily
Study: 9433365
Drug: On demand
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: On demand treatment with cetirizine
Study: 8357678
Drug: Topical prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical prostaglandin E2 (PGE2) gel at a dose of 0.3 mg twice daily for 10 days
Study: 3693870
Drug: Individualized dose
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized dose of amitriptyline calculated by a pharmacokinetic test
Study: 3693870
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose of amitriptyline
Study: 3693870
Drug: Individualized dose
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized dose of amitriptyline
Study: 28966061
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (suture anchor technique)
Study: 19545929
Drug: Gemcitabine 1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1250 mg/m² on day 1 and pemetrexed 500 mg/m² followed by gemcitabine 1250 mg/m² on day 8 of a 3-week cycle (GA arm)
Study: 19545929
Drug: Paclitaxel 120
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 120 mg/m² followed by gemcitabine 1000 mg/m² on days 1 and 8 of a 3-week cycle (PG arm)
Study: 18974515
Drug: Two hours
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two hours occlusion therapy
Study: 18974515
Drug: Four hours
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four hours occlusion therapy
Study: 18974515
Drug: Six hours
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Six hours occlusion therapy
Study: 18974515
Drug: Full-time occlusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-time occlusion therapy
Study: 16828460
Drug: 1-day behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-day behavioral group treatment (BGT) program
Study: 16828460
Drug: 2-day cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-day cognitive-behavioral group treatment (CBGT) program
Study: 1360452
Drug: Combination FSH/hMG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination FSH/hMG
Study: 29666901
Drug: Subcutaneous dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous dexmedetomidine (1 μg/kg)
Study: 29666901
Drug: Intravenous dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dexmedetomidine (1 μg/kg)
Study: 25531119
Drug: 3.0 mEq/l
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 mEq/l dialysate calcium
Study: 25531119
Drug: 2.5 mEq/l
Normalized name: bicarb dialy soln 11 without K calcium (2.5 mEq/L)-magnesium (1.5 mEq/L) HEMODIALYS SOLUTION, NON-ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mEq/l dialysate calcium
Study: 12725416
Drug: Estradiol valerate
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol valerate 2 mg/dienogest 2 mg (E2V/DNG)
Study: 12725416
Drug: Estradiol 2
Normalized name: estradiol 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol 2 mg/norethisterone acetate 1 mg (E2/NETA)
Study: 1655056
Drug: Azithromycin 1
Normalized name: azithromycin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 1 g in a single dose
Study: 1655056
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg in a single dose on day 1 followed by 250 mg once daily for 2 days
Study: 1655056
Drug: Doxycycline 200
Normalized name: doxycycline 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 200 mg in a loading dose followed by 100 mg every 12 h for 7 days
Study: 6820887
Drug: Futraful (more
Approvals — FDA: no, EMA: no, PMDA: no
Description: Futraful (more than 60 g)
Study: 6820887
Drug: Method II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Method II (large dose MMC) plus Futraful
Study: 29532291
Drug: Caffeine (CAF)
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine (CAF) 6 mg kg-1
Study: 29532291
Drug: Placebo (PL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PL) 6 mg kg-1 of maltodextrin
Study: 28130432
Drug: Azithromycin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (2 g)
Study: 25811544
Drug: L-glutamine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-glutamine (0.3 g·kg‐1·day‐1 + 0.3 g·kg‐1·day‐1 maltodextrin)
Study: 10956377
Drug: L-glutamine
Normalized name: L-Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-glutamine
Study: 25811544
Drug: Placebo (maltodextrin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (maltodextrin, 0.6 g·kg‐1·day‐1)
Study: 24092942
Drug: Blood pressure
Normalized name: Blood Pressure Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood pressure lowering regimens (various drug classes including ACE inhibitors, calcium antagonists, diuretics/β blockers)
Study: 19153290
Drug: Crosseal (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crosseal (2 mL sprayed under the skin flap)
Study: 16199249
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg/d for 10 days
Study: 10193720
Drug: Paroxetine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine at 20 mg once a day
Study: 8520811
Drug: MID 10
Normalized name: Revlimid 10mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: MID 10 mg + 150 mg fluconazole (FLU)
Study: 8520811
Drug: MID 10
Normalized name: Revlimid 10mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: MID 10 mg
Study: 8520811
Drug: MID 10
Normalized name: Revlimid 10mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: MID 10 mg after FLU
Study: 8520811
Drug: MID 10
Normalized name: Revlimid 10mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: MID 10 mg after 750 mg erythromycin (ERY)
Study: 8520811
Drug: MID 10
Normalized name: Revlimid 10mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: MID 10 mg alone
Study: 2271746
Drug: Midaglizole 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midaglizole 150 mg
Study: 2271746
Drug: Midaglizole 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midaglizole 200 mg
Study: 2271746
Drug: Midaglizole 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midaglizole 300 mg
Study: 2271746
Drug: Midaglizole 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midaglizole 500 mg
Study: 2271746
Drug: Midaglizole 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midaglizole 200 mg (30 min after breakfast)
Study: 2271746
Drug: Midaglizole 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midaglizole 200 mg t.i.d. (20 min before meals for 7 days)
Study: 2271746
Drug: Midaglizole (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midaglizole (all doses)
Study: 7416592
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 50 mg of naloxone
Study: 7416592
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion of normal saline
Study: 31831920
Drug: Mupirocin 2%
Normalized name: MUPIROCIN 2% OINT
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mupirocin 2% and Sucralfate 7% combination
Study: 27379961
Drug: Midcooling (facial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midcooling (facial water spray and menthol mouth rinse)
Study: 19265095
Drug: Class I
Normalized name: HLA class I antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Class I antiarrhythmic drugs (flecainide, propafenone)
Study: 19265095
Drug: Class III
Normalized name: HLA class III antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Class III antiarrhythmic drug (amiodarone)
Study: 19265095
Drug: Beta blockers
Normalized name: BETA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blockers and rate limiting calcium blockers, digoxin
Study: 11522497
Drug: epalrestat (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: epalrestat (150 mg/day) for 5 years
Study: 9640123
Drug: Target Controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target Controlled Infusion of Propofol
Study: 9640123
Drug: Manually Controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manually Controlled Infusion of Propofol
Study: 26188896
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of procaine 0.5% at 4-5 ml/h for 48 hours via elastomeric pump
Study: 26188896
Drug: Standard post-operative
Normalized name: Sx1 Medicated Post-Operative System KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard post-operative pain regimen of metamizole 1 g and/or ketorolac 3% - 30 mg
Study: 17237328
Drug: Combined iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined iron (10 mg) and zinc (10 mg) supplementation for 6 months
Study: 17237328
Drug: Iron (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron (10 mg) supplementation for 6 months
Study: 17237328
Drug: Zinc (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc (10 mg) supplementation for 6 months
Study: 17237328
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A capsules (VAC) administration
Study: 7786974
Drug: Relaxation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation therapy combined with anti-depressive medication
Study: 7786974
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving only anti-depressive medication
Study: 1972349
Drug: Xamoterol 200
Normalized name: xamoterol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xamoterol 200 mg twice daily for 3 months
Study: 119258
Drug: +amphetamine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: +amphetamine (10 mg)
Study: 119258
Drug: +/-fenfluramine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: +/-fenfluramine (30 mg and 60 mg)
Study: 25731132
Drug: Self-management intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-management intervention targeting cognitive dysfunction, including education on cognitive function, self-awareness training, compensatory strategies, and problem-solving therapy; formal working memory training in a subgroup.
Study: 24083804
Drug: eplerenone (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: eplerenone (target dose 50mg)
Study: 9833847
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg abacavir twice daily
Study: 9833847
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg abacavir twice daily